These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 2566552)

  • 1. [The immunohistochemical growth fraction (Ki-67) of breast cancers: relations to tumor spread, tumor morphology and receptor testing].
    Weikel W; Beck T; Rosenthal H; Herzog R
    Geburtshilfe Frauenheilkd; 1989 Mar; 49(3):277-82. PubMed ID: 2566552
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Tumor properties of primary tumors and local recurrence of breast cancer].
    Torsten U; Opri F; Moreno-Richter I; Weitzel HK
    Zentralbl Gynakol; 1993; 115(3):99-104. PubMed ID: 8385409
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Effect of the proliferation rate on the course of node negative breast carcinoma].
    Mitze M; Weikel W; Brumm C; Lippold R; Knapstein PG
    Geburtshilfe Frauenheilkd; 1995 Jun; 55(6):299-305. PubMed ID: 7657137
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Minimal breast cancer: analysis of proliferative activity using a monoclonal antibody to proliferating cell nuclear antigen (PCNA) and its relationship to histological grade and prognosis.
    Lanzafame S; Magro G; Broggi B
    Pathologica; 1994 Apr; 86(2):150-6. PubMed ID: 7936757
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Topoisomerase IIalpha expression in breast cancer: correlation with outcome variables.
    Depowski PL; Rosenthal SI; Brien TP; Stylos S; Johnson RL; Ross JS
    Mod Pathol; 2000 May; 13(5):542-7. PubMed ID: 10824926
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PCNA/cyclin expression in breast carcinomas: its relationships with Ki-67, ER, PgR immunostainings and clinico-pathologic aspects.
    Tuccari G; Rizzo A; Muscarà M; Giuffrè G; Barresi G
    Pathologica; 1993; 85(1095):47-55. PubMed ID: 8100059
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Assessment of proliferative rate of breast cancer by Ki-67 monoclonal antibody.
    Marchetti E; Querzoli P; Marzola A; Bagni A; Ferretti S; Fabris G; Nenci I
    Mod Pathol; 1990 Jan; 3(1):31-5. PubMed ID: 2308919
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Determination of threshold values for determining the size of the fraction of steroid hormone receptor-positive tumor cells in paraffin-embedded breast carcinomas.
    Leers MP; Hoop JG; van Beers M; van Rodijnen N; Pannebakker M; Nap M
    Cytometry B Clin Cytom; 2005 Mar; 64(1):43-52. PubMed ID: 15668953
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Proliferating cell nuclear antigen immunohistochemistry using monoclonal antibody 19A2 and a new antigen retrieval technique has prognostic impact in archival paraffin-embedded node-negative breast cancer.
    Siitonen SM; Kallioniemi OP; Isola JJ
    Am J Pathol; 1993 Apr; 142(4):1081-9. PubMed ID: 7682759
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Progesterone receptors in breast cancer. Comparison of immunohistochemical with biochemical receptor analysis. Relation between hormone receptor content and growth fraction (Ki-67)].
    Ronay G; Sponsel N; Merkle E; Tulusan AH
    Pathologe; 1990 Jan; 11(1):4-9. PubMed ID: 2156252
    [No Abstract]   [Full Text] [Related]  

  • 11. [137 local recurrences after breast carcinoma--a retrospective study].
    Richter IM; Opri F; Torsten U; Weitzel H
    Geburtshilfe Frauenheilkd; 1996 Apr; 56(4):198-203. PubMed ID: 8682285
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Breast cancer cell kinetics: immunocytochemical determination of growth fractions by monoclonal antibody Ki-67 and correlation with flow cytometric S-phase and with some features of tumor aggressiveness.
    Gasparini G; Pozza F; Meli S; Reitano M; Santini G; Bevilacqua P
    Anticancer Res; 1991; 11(6):2015-21. PubMed ID: 1776834
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunohistochemical detection of hormone receptors in breast carcinomas (ER-ICA, PgR-ICA): prognostic usefulness and comparison with the biochemical radioactive-ligand-binding assay (DCC).
    Beck T; Weikel W; Brumm C; Wilkens C; Pollow K; Knapstein PG
    Gynecol Oncol; 1994 May; 53(2):220-7. PubMed ID: 8188083
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic role of a multigene reverse transcriptase-PCR assay in patients with node-negative breast cancer not receiving adjuvant systemic therapy.
    Esteva FJ; Sahin AA; Cristofanilli M; Coombes K; Lee SJ; Baker J; Cronin M; Walker M; Watson D; Shak S; Hortobagyi GN
    Clin Cancer Res; 2005 May; 11(9):3315-9. PubMed ID: 15867229
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Simultaneous immunohistochemical and biochemical hormone receptor assessment in breast cancer provides complementary prognostic information.
    Biesterfeld S; Schröder W; Steinhagen G; Koch R; Veuskens U; Schmitz FJ; Handt S; Böcking A
    Anticancer Res; 1997; 17(6D):4723-9. PubMed ID: 9494596
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Flow cytophotometry parameters, hormone receptors and axillary lymph node status as prognostic factors in primary breast cancer].
    Kaufmann M; Feichter GE; Nhila A; Klinga K; Abel U
    Geburtshilfe Frauenheilkd; 1988 Oct; 48(10):705-9. PubMed ID: 3234702
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hormonal receptors, cell proliferation fraction (Ki-67) and c-erbB-2 amplification in breast cancer. Relationship between differentiation degree and axillary lymph node metastases.
    Sirvent JJ; Santafé M; Salvadó MT; Alvaro T; Raventós A; Palacios J
    Histol Histopathol; 1994 Jul; 9(3):563-70. PubMed ID: 7526910
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Rate of proliferation as a prognostic criterion in endometrial carcinoma--an immunohistochemical analysis with the monoclonal antibody KI-S1].
    Backe J; Gassel AM; Müller T; Schön S; Kaesemann H
    Zentralbl Gynakol; 1997; 119(7):334-42. PubMed ID: 9340973
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunohistochemical localization of metallothionein in human breast cancer in comparison with cathepsin D, stromelysin-1, CD44, extracellular matrix components, P53, Rb, C-erbB-2, EGFR, steroid receptor content and proliferation.
    Ioachim E; Kamina S; Demou A; Kontostolis M; Lolis D; Agnantis NJ
    Anticancer Res; 1999; 19(3A):2133-9. PubMed ID: 10470161
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Image cytometry of aneuploidy, growth fraction (MoAb Ki-67) and hormone receptors (ER, PR) immunocytochemical assays in breast carcinomas.
    Charpin C; Andrac L; Lavaut MN; Andonian C; Fraterno M; Devictor B; Perez-Castillo A; Bonnier P; Piana L
    Anal Cell Pathol; 1990 Oct; 2(6):357-71. PubMed ID: 2275882
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.